Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis

Clinical and Vaccine Immunology

Volumn 19, Issue 3, 2012, Pages 359-364

  Kaur, Ravinder ^a,c   Chen, Shan ^b   Arévalo, Maria T ^b   Xu, Qingfu ^a,c   Chen, Yanping ^b   Zeng, Mingtao ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Texas Tech University Health Sciences Center El Paso   (United States)

^c ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MEMBRANE PROTEIN; PROTEIN TUL4; RECOMBINANT VACCINE; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCISELLA TULARENSIS; GENE EXPRESSION; GENE SEQUENCE; GENETIC IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUL4 GENE; TULAREMIA; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; FEMALE; FRANCISELLA TULARENSIS; GENETIC VECTORS; LIPOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TULAREMIA; VACCINATION; VACCINES, SYNTHETIC;

EID: 84863250722     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05384-11     Document Type: Article

References (34)

1. André S, et al. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72:1497-1503. (Pubitemid 28116938)
2. Boyer JL, Kobinger G, Wilson JM, Crystal RG. 2005. Adenovirus-based genetic vaccines for biodefense. Hum. Gene Ther. 16:157-168. (Pubitemid 40344208)
3. Casadevall A, Pirofski LA. 2006. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91:1-44. (Pubitemid 44286993)
4. Centers for Disease Control and Prevention. 2000. Biological and chemical terrorism: strategic plan for preparedness and response. MMWR Recommend. Rep. 49(RR04):1-14.
5. Centers for Disease Control and Prevention. 2002. Tularemia, United States, 1990-2000. MMWR Morb. Mortal. Wkly. Rep. 51:182-184.
6. Culkin SJ, Rhinehart-Jones T, Elkins KL. 1997. A novel role for B cells in early protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J. Immunol. 158:3277-3284. (Pubitemid 127484044)
7. Dennis DT, et al. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773. (Pubitemid 32525374)
8. Eigelsbach HT, Hornick RB, Tulis JJ. 1967. Recent studies on live tularemia vaccine. Med. Ann. Dist. Columbia 36:282-286.
9. Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH. 1993. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect. Immun. 61:823-829. (Pubitemid 23059636)
10. Eneslätt K, et al. 2011. Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis. Eur. J. Immunol. 41:974-980.
11. Forestal CA, et al. 2007. Francisella tularensis has a significant extracellular phase in infected mice. J. Infect. Dis. 196:134-137. (Pubitemid 46982747)
12. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59:2922-2928.
13. Golovliov I, et al. 1995. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 13:261-267.
14. Hangalapura BN, et al. 2011. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine 29:2313-2321.
15. He TC, et al. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95:2509-2514.
16. Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. 2005. Vaccination strategies for Francisella tularensis. Adv. Drug Deliv Rev. 57:1403-1414. (Pubitemid 40796128)
17. Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW. 2008. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol. Rev. 225:244-255.
18. Koskela P, Salminen A. 1985. Humoral immunity against Francisella tularensis after natural infection. J. Clin. Microbiol. 22:973-979. (Pubitemid 16222723)
19. Lubeck MD, et al. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651-658. (Pubitemid 27264975)
20. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
21. Rhinehart-Jones TR, Fortier AH, Elkins KL. 1994. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect. Immun. 62:3129-3137. (Pubitemid 24232092)
22. Sandström G, Tarnvik A, Wolf-Watz H. 1987. Immunospecific T-lymphocyte stimulation by membrane proteins from Francisella tularensis. J. Clin. Microbiol. 25:641-644. (Pubitemid 17041859)
23. Shen H, Chen W, Conlan JW. 2004. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22:2116-2121. (Pubitemid 38626048)
24. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335. (Pubitemid 34087555)
25. Sjöstedt A, Sandstrom G, Tarnvik A. 1992. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect. Immun. 60:2855-2862.
26. Sjöstedt A, Sandstrom G, Tarnvik A, Jaurin B. 1990. Nucleotide sequence and T cell epitopes of a membrane protein of Francisella tularensis. J. Immunol. 145:311-317. (Pubitemid 20217417)
27. Surcel HM. 1990. Diversity of Francisella tularensis antigens recognized by human T lymphocytes. Infect. Immun. 58:2664-2668.
28. Tan Y, Hackett NR, Boyer JL, Crystal RG. 2003. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14:1673-1682. (Pubitemid 37452877)
29. Vorburger SA, Hunt KK. 2002. Adenoviral gene therapy. Oncologist 7:46-59. (Pubitemid 34151107)
30. Xu Q, Arevalo MT, Pichichero ME, Zeng M. 2006. A new complementing cell line for replication-incompetent E1-deleted adenovirus propagation. Cytotechnology 51:133-140. (Pubitemid 44875817)
31. Zeng M, Cerniglia GJ, Eck SL, Stevens CW. 1997. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum. Gene Ther. 8:1025-1032. (Pubitemid 27308200)
32. Zeng M, et al. 2001. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 31:260-262. (Pubitemid 32747578)
33. Zeng M, et al. 2007. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25:7540-7548. (Pubitemid 47503495)
34. Zeng M, Xu Q, Hesek ED, Pichichero ME. 2006. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24:662-670. (Pubitemid 43017833)